Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Author Correction: Immune resp...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Author Correction: Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice

Author Correction: Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice

Bibliographic Details
Main Authors: Tomoyuki Homma, Noriyo Nagata, Masayuki Hashimoto, Naoko Iwata-Yoshikawa, Naomi M. Seki, Nozomi Shiwa-Sudo, Akira Ainai, Keiji Dohi, Eiji Nikaido, Akiko Mukai, Yuuta Ukai, Takayuki Nakagawa, Yusuke Shimo, Hiroki Maeda, Seiki Shirai, Miwa Aoki, Takuhiro Sonoyama, Mamoru Sato, Masataka Fumoto, Morio Nagira, Fumihisa Nakata, Takao Hashiguchi, Tadaki Suzuki, Shinya Omoto, Hideki Hasegawa
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-024-52772-3
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1038/s41598-024-52772-3

Similar Items

  • Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice
    by: Tomoyuki Homma, et al.
    Published: (2022-12-01)
  • Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan
    by: Takuhiro Sonoyama, et al.
    Published: (2023-12-01)
  • A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults
    by: Satoshi Iwata, et al.
    Published: (2024-04-01)
  • A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults
    by: Iwata, S, et al.
    Published: (2024)
  • Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study
    by: Masaya Fujitani, et al.
    Published: (2025-03-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs